Integration of PARP Inhibitors for the Treatment of Ovarian Cancer: Significance for Payers and Specialty Pharmacies

Date:               Thursday, May 1, 2019

Location:         Wynn and Encore Hotels
3131 S Las Vegas Boulevard
Las Vegas, Nevada 89109

Room: Beethoven

Time:               7:00 am – 8:30 am
                        *Breakfast will be available

Program Description
Hereditary ovarian cancers have been linked to the presence of germline mutations in the tumor suppression genes as well as breast cancer type 1 and 2 susceptibility genes (BRCA 1 and BRCA 2). There are multiple approved indications for the use of PARP inhibitors, and their use has been shown to extend progression-free survival in patients. Companion diagnostic tests for the presence of mutated BRCA may help to identify which patients will benefit most from PARP inhibitor therapy. As part of the health care team, pharmacists engage in significant roles from helping to identify which patients may benefit most from PARP inhibitor therapies to communicating with patients about therapy expectations, adherence, and monitoring plans while they are receiving PARP inhibitors.

Educational Objectives
  • Analyze approved PARP inhibitor therapies for ovarian cancer through applied knowledge of clinical trial data, mechanisms of action, and adverse effect profiles 
  • Explain appropriate diagnostic testing for use of PARP inhibitors in the treatment of ovarian cancer 
  • Examine the role of pharmacists within the collaborative care team for effective therapy management for patients with ovarian cancer

Faculty Presenters

Laura Alwan, PharmD, BCOP
Oncology Clinical Pharmacist
University of Washington Medical Center
Seattle Cancer Care Alliance
Seattle, Washington

Jason Bergsbaken, PharmD, BCOP
Pharmacy Coordinator, Regional Oncology Services
UW Health
Madison, Wisconsin

This activity is supported by an educational grant from Tesaro.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-19-056-L01-P. The activity is available for CE credit for May 2, 2019.

Obtaining Credit:
All participants who attended the live symposium need to log on to their Pharmacy Times Continuing Education™ account on to complete an online evaluation form and request their credit. Detailed instructions on obtaining credit will be provided at the session. Credit must be requested no later than July 2, 2019.